| Literature DB >> 21394199 |
Rouyanne T Ras1, Peter L Zock, Richard Draijer.
Abstract
BACKGROUND: Tea consumption is associated with a lower risk of cardiovascular disease including stroke. Direct effects of tea components on the vasculature, particularly the endothelium, may partly explain this association.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21394199 PMCID: PMC3048861 DOI: 10.1371/journal.pone.0016974
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of the study selection procedure.
*One study was identified after the systematic search through March 2009.
Overview and characteristics of included studies.
| Subject characteristics | Treatment characteristics | %FMD outcomes | ||||||||||
| Author and year | Study design | Total no of subjects | Mean age (yr) | Gender (% male) | Health status | Green or black | Dose of tea (mL/day) | Duration | Mean baseline (%) | Net response (%) | 95% CI | Quality Score |
| Alexopoulos et al. 2008 | R, PCW, SB, CO, dist | 14 | 30 | 64 | healthy | green | 450 | ST: 30 (/60/90) min | 4.4 | 3.7 | (0.7, 6.7) | 5 |
| Ardalan et al. 2007 | NR, PCW, BNR, CO, prox | 15 | 37.2 | 60 | RTR | black | 500 | ST: 120 min | 7.3 | 6.7 | (4.4, 9.1) | 4 |
| Duffy et al. 2001 | R, PCW, SB, CO, prox | 50 | 55 | 78 | CAD | black | 450 | ST: 120 min | 5.7 | 3.7 | (2.6, 4.8) | 6 |
| Duffy et al. 2001 | R, PCW, SB, CO, prox | 50 | 55 | 78 | CAD | black | 900 | LT: 28 days | 6.1 | 3.4 | (2.3, 4.5) | 6 |
| Grassi et al. 2009 | R, PCC, DB, CO, dist | 19 | 32.9 | 100 | healthy | black | 120 | ST upon LT: 7 days | 7.8 | 1.2 | (0.4, 2.0) | 7 |
| Grassi et al. 2009 | R, PCC, DB, CO, dist | 19 | 32.9 | 100 | healthy | black | 240 | ST upon LT: 7 days | 7.8 | 1.3 | (0.5, 2.1) | 7 |
| Grassi et al. 2009 | R, PCC, DB, CO, dist | 19 | 32.9 | 100 | healthy | black | 480 | ST upon LT: 7 days | 7.8 | 1.8 | (1.2, 2.4) | 7 |
| Grassi et al. 2009 | R, PCC, DB, CO, dist | 19 | 32.9 | 100 | healthy | black | 960 | ST upon LT: 7 days | 7.8 | 2.5 | (2.0, 3.0) | 7 |
| Hodgson et al. 2002 | R, PCW, SB, PA, dist | 11/10 | 59.1 | 76 | MHC | black | 5×250 | LT: 28 days | 5.1 | 2.3 | (0.7, 3.9) | 6 |
| Hodgson et al. 2005 | R, PCW, SB, CO, dist | 20 | 62.1 | NA | CAD | black | 3×250 | ST: 60–90 min | 4.3 | 0.9 | (−0.7, 2.5) | 6 |
| Hodgson et al. 2005 | R, PCW, SB, CO, dist | 20 | 62.1 | NA | CAD | black | 3×250 | ST: 60–90 min | 5.4 | 0.5 | (−1.5, 2.5) | 6 |
| Jochmann et al. 2008 | RA, PCW, SB, CO, dist | 21 | 58.7 | 0 | healthy | green | 500 | ST: 120 min | 6.4 | 3.8 | (2.5, 5.1) | 5.5 |
| Jochmann et al. 2008 | RA, PCW, SB, CO, dist | 21 | 58.7 | 0 | healthy | black | 500 | ST: 120 min | 6.4 | 2.7 | (1.2, 4.2) | 5.5 |
| Lorenz et al. 2007 | R, PCW, SB, CO, dist | 16 | 59.5 | 0 | healthy | black | 500 | ST: 120 min | 6.9 | 2.2 | (0.4, 4.0) | 5.5 |
| Park et al. 2009 | R, PCW, OL, PA, dist | 20/17 | 61.5 | 93 | CKD | green | 500 | LT: 28 days | 5.7 | 4.2 | (2.1, 6.2) | 5 |
Duffy et al. [19] (both intervention arms) and Hodgson et al. [22] used a respective control period for each intervention period; Grassi et al. [41] and Jochmann et al. [23] used a single control period for all intervention periods. In case of multiple study arms, the intervention is specified between brackets.
Study design is R (randomized), NR (not randomized), RA (randomization assumed), PCW (placebo controlled with water), PCC (placebo controlled with caffeine), DB (double blinded), SB (single blinded), BNR (blinding not reported), OL (open label), CO (crossover), PA (parallel), dist (distal occlusion), prox (proximal occlusion).
For parallel studies: number in control group/number in treatment group.
Health status is healthy, MHC (mildly hypercholesterolemic), CAD (coronary artery disease), RTR (renal transplant recipients), CKD (chronic kidney disease).
The dosage of tea is expressed in mL tea per day. Only Grassi et al. [41] did not report the dosage of tea in such a unit and for that study, the volume of tea consumed was estimated from the concentration of flavonoids consumed per day.
Duration is LT (long-term/chronic) or ST (short-term/acute).
Mean baseline outcome (reference outcome) is the mean FMD at the end of the control period for crossover studies. For parallel studies, mean baseline outcome is the mean baseline FMD of the active treatment group. For Alexopoulos et al. [26], mean baseline outcome is the mean baseline FMD of the active treatment period (no endpoint FMD values reported).
Net response was calculated by subtracting the mean FMD at the end of the active treatment period from the mean FMD at the end of the control period in case of crossover studies. For parallel studies, the mean FMD change from baseline in the control group was subtracted from the mean FMD change from baseline in the active treatment group.
NA not available.
FMD measured with semi-automated edge-detection system.
Figure 2Funnel plot.
The net FMD responses are expressed against their respective precisions (1/SE) in 15 study arms. The net responses are scattered around the pooled overall effect of 2.6% (dotted line). In case the most extreme outlier (red circle) is excluded from the analyses, the net responses are more symmetrically scattered around the adjusted pooled overall effect of 2.4% (red dotted line).
Figure 3Forest plot.
The net FMD responses and 95% confidence intervals of 15 study arms from 9 studies investigating the effect of tea on FMD are shown. The dotted line indicates the pooled overall FMD effect (2.6%), in which each study arm was weighed by the inverse of its variance (1/SE2). In case of multiple study arms, the intervention is specified between brackets.
Effect of tea on FMD within and between different subgroups.
| Trial characteristic | Stratification variable | No of study arms | Pooled FMD effect (%) | 95% CI | P-value |
|
| |||||
| Health status | Diseased | 6 | 3.1 | (2.1; 4.2) | <0.001 |
| Healthy | 9 | 2.3 | (1.5; 3.0) | <0.001 | |
| Δ | 15 | 0.9 | (−0.4; 2.2) | 0.188 | |
| Baseline FMD | <6.4% | 7 | 2.6 | (1.6; 3.7) | <0.001 |
| ≥6.4% | 8 | 2.5 | (1.7; 3.4) | <0.001 | |
| Δ | 15 | 0.1 | (−1.2; 1.5) | 0.866 | |
| Age | <55 yr | 6 | 2.4 | (1.4; 3.4) | <0.001 |
| ≥55 yr | 9 | 2.7 | (1.8; 3.6) | <0.001 | |
| Δ | 15 | −0.3 | (−1.6; 1.1) | 0.702 | |
| Dose | ≤500 mL | 10 | 2.9 | (2.0; 3.7) | <0.001 |
| >500 mL | 5 | 2.0 | (0.9; 3.2) | <0.001 | |
| Δ | 15 | 0.8 | (−0.6; 2.2) | 0.259 | |
| Quality | Low quality (<6 points) | 6 | 3.7 | (2.7; 4.7) | <0.001 |
| High quality (≥6 points) | 9 | 2.0 | (1.4; 2.7) | <0.001 | |
| Δ | 15 | 1.7 | (0.5; 2.9) | 0.005 | |
|
| |||||
| Type of tea | Black tea | 12 | 2.3 | (1.5; 3.1) | <0.001 |
| Type of placebo | Water | 11 | 3.0 | (2.1; 4.0) | <0.001 |
| Duration | Short-term | 8 | 3.0 | (1.5; 4.4) | 0.002 |
| Cuff placement | Distal | 12 | 2.1 | (1.5; 2.7) | <0.001 |
For continuous variables, studies were divided in subgroups based on their medians: 6.4% for baseline FMD, 55 years for age, 500 mL for dose of tea, and 6.0 points for quality.
For type of tea, type of placebo, study duration, and cuff placement, we performed sensitivity analysis due to limited number of studies (<5) in one of the subgroups.
For the subgroup with short-term duration, we excluded the long-term study arms (>2 weeks) and the study arms that investigated acute upon longer-term effects.
Post-hoc analysis.